NewAmsterdam Pharma's Upcoming Investor Conferences
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), a prominent player in the biopharmaceutical industry, is gearing up for a series of important investor conferences this December. This late-stage company is focused on developing innovative oral therapies aimed at reducing cholesterol levels in patients at risk for cardiovascular disease (CVD). As they highlight their mission to provide effective treatments for individuals with elevated low-density lipoprotein cholesterol (LDL-C) who have not found success with existing options, the upcoming events are a prime opportunity for investors to gain insight into their future direction.
Highlights of the Conferences
The company management team plans to engage with investors at several key conferences. On the agenda for December, they include:
8th Annual Evercore Healthcare Conference
This event will take place on December 2, 2025. Ian Somaiya, the Chief Financial Officer, will have a spotlight moment participating in a fireside chat slated for 3:50 p.m. ET. This session is particularly significant as it will provide insights into the company’s financial strategies and future initiatives.
Citi's 2025 Global Healthcare Conference
The following day, on December 3, 2025, Michael Davidson, M.D., the Chief Executive Officer, alongside Ian Somaiya, will again engage in meaningful discussions about their strategies for advancing healthcare solutions. Their session at 3:15 p.m. ET promises to delve deeper into the company's mission to improve healthcare outcomes.
Piper Sandler 37th Annual Healthcare Conference
Wrapping up their conference tour, on December 4, 2025, NewAmsterdam representatives will speak at the Piper Sandler conference in New York City. Michael Davidson, M.D., and Ian Somaiya will lead the conversation at 8:00 a.m. ET, reflecting on their groundbreaking developments and potential market impact.
Webcast Availability
For those unable to attend the conferences in person, NewAmsterdam Pharma will provide live webcasts of the fireside chats. Investors and interested parties can find this information on the company's investor relations website, with archived replays available shortly after each event. This accessibility ensures that stakeholders stay informed about the company’s latest progress and future plans.
About NewAmsterdam Pharma
Founded with the goal of enhancing treatment options for metabolic diseases, NewAmsterdam Pharma aims to address the unmet need for effective and well-tolerated LDL-lowering therapies. Their lead candidate, obicetrapib, is currently being tested in multiple phase 3 trials, exploring its efficacy as a standalone treatment or in combination with ezetimibe. Through these trials, they aim to provide an innovative alternative for patients who struggle with CVD risk.
Contact Information
Company Contact
Matthew Philippe
P: 1-917-882-7512
Email: matthew.philippe@newamsterdampharma.com
Media Contact
Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
Email: cedgington@realchemistry.com
Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
Email: austin.murtagh@precisionaq.com
Frequently Asked Questions
What is NewAmsterdam Pharma focused on?
NewAmsterdam Pharma is dedicated to developing innovative oral therapies for patients at risk of cardiovascular disease who have elevated LDL-C.
When will the investor conferences take place?
The investor conferences are scheduled for December 2, 3, and 4, 2025.
Who will represent the company at the conferences?
Michael Davidson, M.D., and Ian Somaiya, among others, will represent the company during these events.
How can I watch the investor talks?
Live webcasts will be available on NewAmsterdam's investor relations website, along with archived replays.
What therapy is NewAmsterdam currently researching?
The company is investigating obicetrapib, a novel CETP inhibitor, in phase 3 trials as an LDL-lowering therapy.
